Safety and precautions for using Apremilast (Otelor) in children and special groups

Apremilast (Apremilast) is an oral phosphodiesterase4 (PDE4) inhibitor, mainly used for the treatment of moderate to severe psoriasis and psoriatic arthritis. By inhibiting PDE4, apremilast can increase intracellular cAMP levels, thereby regulating the expression of inflammatory mediators and reducing inflammatory responses. Although its efficacy and safety in adult patients have been widely verified, its application in children and special populations (such as the elderly, patients with hepatic and renal insufficiency, and those with low immune function) still requires caution and needs to be combined with individualized management strategies.

Clinical data on apremilast are relatively limited in pediatric patients. Most of the current research and approved indications are for adults aged 18 years and above. Since children's metabolism and immune systems are immature, their pharmacokinetics and pharmacodynamic responses may be different from those of adults, so there is a risk of drug overdose or side effects. For adolescent patients with psoriasis or psoriatic arthritis, doctors usually weigh the severity of the disease against the potential risks, carefully evaluate whether to use apremilast, and conduct adequate risk information and follow-up plan development before treatment. During treatment, weight changes, appetite, mental status, and routine blood indicators need to be closely monitored to detect possible adverse reactions in a timely manner.

Elderly patients are another category of special population for apremilast. The elderly have reduced metabolic capacity and reduced liver and kidney functions. In addition, they are often accompanied by multiple underlying diseases and multi-drug sharing, which may increase the risk of adverse drug reactions. For example, mild to moderate gastrointestinal effects (eg, diarrhea, nausea), weight loss, and headaches may be more pronounced in older adults. In order to ensure safety, doctors usually evaluate liver and kidney function before taking medication, adjust the dosage if necessary, and regularly follow up on drug tolerance. At the same time, attention should be paid to the mental health and self-care ability of elderly patients to avoid a decrease in compliance due to drug discomfort.

For special groups with hepatic and renal insufficiency or low immune function, caution is also required when using apremilast. Patients with mild to moderate renal impairment can usually tolerate it at conventional doses, but those with severe renal impairment need to adjust the dose to avoid drug accumulation leading to adverse reactions. Although current studies show that the safety of the drug is acceptable in patients with hepatic insufficiency, liver function indicators still need to be monitored regularly. For people with low immune function, such as patients with HIV infection or long-term use of immunosuppressants, apremilast may increase the risk of infection. Therefore, infection prevention and control measures should be strengthened during treatment, including regular physical examinations and routine blood monitoring.

In general, children and special groups need to strictly follow medical instructions and carry out individualized management when using apremilast. The severity of the disease, patient's physical condition, liver and kidney function, and potential risk of complications should be fully assessed before treatment. During treatment, weight, blood indicators, liver and kidney function, and psychological state need to be monitored regularly, and adverse drug reactions and changes in efficacy need to be paid close attention to. Under the professional guidance of doctors, through individualized dose adjustment and follow-up management, children and special groups can still safely and effectively benefit from apremilast treatment, thereby improving the symptoms and quality of life of psoriasis or psoriatic arthritis.

Reference materials:https://www.drugs.com/